Ardelyx Stock Is Rallying – What Is Making Retail So Bullish?

• Ibsrela achieved $274 million in revenue in 2025, representing 73% growth vs. 2024
• The company expects 2029 IBSRELA revenue to be $1 billion. 
• It expects Ibsrela FY2026 revenue to be between $410 and $430 million, up 50% from 2025. 

Shares of Ardelyx rallied on Thursday after it announced its preliminary guidance for the fiscal year 2026 that buoyed retail traders. 

The company said that majority of its full-year 2026 revenue will come from its  drug Ibsrela, a first-in-class therapy for irritable bowel syndrome with constipation. It expects revenue to be between $410 and $430 million, representing growth of at least 50% compared to 2025.

The company said it expects its full-year 2026 Xphozah revenue is expected to be between $110 and $120 million. Ardelyx’s Xphozah is a FDA-approved drug that is given to lower phosphorus levels in adults with chronic kidney disease on dialysis. 

“We enter 2026 exceptionally well positioned to deliver significant growth and long-term value creation as we invest in our business to accelerate our commercial opportunities,” said Mike Raab, president and chief executive officer at Ardelyx. 

Shares in the company soared nearly 17% at the time of writing. 

Ibsrela Potential

Ardelyx launched Ibsrela in the U.S. in 2022 and has since been a success for the company. The company expects 2029 Ibsrela revenue to be $1 billion. 

The drug generated a revenue of about $87 million in the fourth quarter of 2025 compared to $53.8 million in the year-ago quarter. Ibsrela finished 2025 with full year revenue totaling approximately $274 million, 73% growth compared to 2024, it said. 

It also said that a late-stage clinical trial evaluating Ibsrela in patients with chronic idiopathic constipation (CIC) has commenced and is expected to be completed in the second half of 2027.

How Did Stocktwits Users React?

Retail sentiment around ARDX trended in ‘extremely bullish’ territory amid ‘high’ message volume. 

One bullish user said the company is going to ‘overachieve’ in 2026. 

https://stocktwits.com/Bfunk17/message/641220312

Another user said that their portfolio saw a big bounce due to the recent announcement.

https://stocktwits.com/elisworld/message/641225054

Shares of Ardenyx are up nearly 26% over the past year. 
 

Share

·

Add us on